VRTX — VERTEX PHARMACEUTICALS INC

Ownership history in Prosight Management, LP  ·  5 quarters on record

This page tracks every 13F SEC filing in which Prosight Management, LP reported a position in VERTEX PHARMACEUTICALS INC (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
6.75% (2021 Q1)
Avg. % of fund
3.34%
First filed
2020 Q4
Last filed
2025 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 20,500 +5,500 +36.7% 1.87% $8.0M $391.64
2021 Q3 REDUCED 15,000 -12,100 -44.6% 1.50% $2.7M $181.39
2021 Q2 REDUCED 27,100 -11,250 -29.3% 3.42% $5.5M $201.63
2021 Q1 ADDED 38,350 +9,450 +32.7% 6.75% $8.2M $214.89
2020 Q4 INITIATED 28,900 — — 3.16% $6.8M $236.34
% of Fund (quarterly)    VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%
← Back to Prosight Management, LP Holdings